Actinium Pharmaceuticals, Inc. (ATNM)
USD 1.16
(-4.92%)
USD 1.16
(-4.92%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -74.56 Million USD | 29.87% |
| 2022 | -106.32 Million USD | -37.17% |
| 2021 | -77.51 Million USD | -23.39% |
| 2020 | -62.82 Million USD | -702.76% |
| 2019 | -7.82 Million USD | 41.65% |
| 2018 | -13.41 Million USD | 22.93% |
| 2017 | -17.39 Million USD | 15.2% |
| 2016 | -20.51 Million USD | 19.14% |
| 2015 | -25.37 Million USD | -295.09% |
| 2014 | -6.42 Million USD | -19.49% |
| 2013 | -5.37 Million USD | 1.88% |
| 2012 | -5.47 Million USD | -4671.27% |
| 2011 | 119.85 Thousand USD | 100.25% |
| 2010 | 59.85 Thousand USD | -9.85% |
| 2009 | 66.39 Thousand USD | 39.45% |
| 2008 | 47.6 Thousand USD | 61.24% |
| 2007 | 29.52 Thousand USD | 110.39% |
| 2006 | 14.03 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -82.07 Million USD | -10.07% |
| 2024 Q2 | -84.18 Million USD | -2.57% |
| 2023 Q1 | -92.06 Million USD | 13.42% |
| 2023 FY | -74.56 Million USD | 29.87% |
| 2023 Q2 | -88.93 Million USD | 3.39% |
| 2023 Q3 | -80.76 Million USD | 9.19% |
| 2023 Q4 | -74.56 Million USD | 7.68% |
| 2022 Q3 | -109.21 Million USD | 3.93% |
| 2022 FY | -106.32 Million USD | -37.17% |
| 2022 Q2 | -113.68 Million USD | -58.28% |
| 2022 Q4 | -106.32 Million USD | 2.64% |
| 2022 Q1 | -71.82 Million USD | 7.35% |
| 2021 Q4 | -77.51 Million USD | 5.01% |
| 2021 Q3 | -81.61 Million USD | -0.28% |
| 2021 Q2 | -81.38 Million USD | -13.63% |
| 2021 Q1 | -71.61 Million USD | -14.0% |
| 2021 FY | -77.51 Million USD | -23.39% |
| 2020 FY | -62.82 Million USD | -702.76% |
| 2020 Q1 | -4.63 Million USD | 40.72% |
| 2020 Q3 | -47.35 Million USD | 9.58% |
| 2020 Q4 | -62.82 Million USD | -32.66% |
| 2020 Q2 | -52.37 Million USD | -1028.99% |
| 2019 Q2 | -18.1 Million USD | -116.79% |
| 2019 Q3 | -13.06 Million USD | 27.85% |
| 2019 Q4 | -7.82 Million USD | 40.09% |
| 2019 FY | -7.82 Million USD | 41.65% |
| 2019 Q1 | -8.35 Million USD | 37.73% |
| 2018 FY | -13.41 Million USD | 22.93% |
| 2018 Q4 | -13.41 Million USD | 9.42% |
| 2018 Q3 | -14.8 Million USD | 31.05% |
| 2018 Q2 | -21.47 Million USD | 19.76% |
| 2018 Q1 | -26.76 Million USD | -53.82% |
| 2017 Q2 | -11.45 Million USD | 32.96% |
| 2017 FY | -17.39 Million USD | 15.2% |
| 2017 Q4 | -17.39 Million USD | 15.3% |
| 2017 Q3 | -20.54 Million USD | -79.31% |
| 2017 Q1 | -17.08 Million USD | 16.72% |
| 2016 Q1 | -22.02 Million USD | 13.2% |
| 2016 Q3 | -15.52 Million USD | 23.76% |
| 2016 Q2 | -20.36 Million USD | 7.55% |
| 2016 Q4 | -20.51 Million USD | -32.15% |
| 2016 FY | -20.51 Million USD | 19.14% |
| 2015 Q4 | -25.37 Million USD | -2.49% |
| 2015 Q2 | -25.85 Million USD | -35.43% |
| 2015 Q1 | -19.09 Million USD | -197.28% |
| 2015 Q3 | -24.76 Million USD | 4.24% |
| 2015 FY | -25.37 Million USD | -295.09% |
| 2014 Q2 | -14.61 Million USD | -152.72% |
| 2014 Q4 | -6.42 Million USD | 45.34% |
| 2014 Q3 | -11.75 Million USD | 19.6% |
| 2014 FY | -6.42 Million USD | -19.49% |
| 2014 Q1 | -5.78 Million USD | -7.59% |
| 2013 FY | -5.37 Million USD | 1.88% |
| 2013 Q4 | -5.37 Million USD | -34.72% |
| 2013 Q3 | -3.99 Million USD | 28.92% |
| 2013 Q2 | -5.61 Million USD | -77.35% |
| 2013 Q1 | -3.16 Million USD | 42.23% |
| 2012 FY | -5.47 Million USD | -4671.27% |
| 2012 Q3 | -2.49 Million USD | -3606.58% |
| 2012 Q2 | 71.11 Thousand USD | 11.08% |
| 2012 Q1 | 64.02 Thousand USD | 10.35% |
| 2012 Q4 | -5.47 Million USD | -119.69% |
| 2011 FY | 119.85 Thousand USD | 100.25% |
| 2011 Q4 | 58.01 Thousand USD | 8.24% |
| 2011 Q3 | 53.6 Thousand USD | 0.0% |
| 2011 Q2 | 53.6 Thousand USD | -14.48% |
| 2011 Q1 | 62.67 Thousand USD | 41884.67% |
| 2010 Q1 | 71.81 Thousand USD | 8.17% |
| 2010 FY | 59.85 Thousand USD | -9.85% |
| 2010 Q2 | 75.19 Thousand USD | 4.7% |
| 2010 Q3 | 53.48 Thousand USD | -28.87% |
| 2010 Q4 | -150.00 USD | -100.28% |
| 2009 Q1 | 57.85 Thousand USD | 21.53% |
| 2009 Q4 | 66.39 Thousand USD | 4.98% |
| 2009 Q3 | 63.24 Thousand USD | 9.01% |
| 2009 Q2 | 58.01 Thousand USD | 0.27% |
| 2009 FY | 66.39 Thousand USD | 39.45% |
| 2008 Q4 | 47.6 Thousand USD | 6.78% |
| 2008 Q2 | 39.73 Thousand USD | 8.24% |
| 2008 Q3 | 44.58 Thousand USD | 12.22% |
| 2008 FY | 47.6 Thousand USD | 61.24% |
| 2008 Q1 | 36.7 Thousand USD | 24.32% |
| 2007 Q3 | 25.02 Thousand USD | 22.84% |
| 2007 FY | 29.52 Thousand USD | 110.39% |
| 2007 Q2 | 20.37 Thousand USD | 45.18% |
| 2007 Q1 | 14.03 Thousand USD | 0.0% |
| 2007 Q4 | 29.52 Thousand USD | 17.98% |
| 2006 Q4 | 14.03 Thousand USD | 0.0% |
| 2006 FY | 14.03 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -4.94 Million USD | -1408.172% |
| Ampio Pharmaceuticals, Inc. | -3.81 Million USD | -1854.495% |
| Armata Pharmaceuticals, Inc. | 106.84 Million USD | 169.785% |
| Azitra, Inc. | -910.04 Thousand USD | -8093.468% |
| Can-Fite BioPharma Ltd. | -4.23 Million USD | -1659.414% |
| Chromocell Therapeutics Corporation | 1.17 Million USD | 6460.52% |
| Calidi Biotherapeutics, Inc. | 5.18 Million USD | 1537.517% |
| CEL-SCI Corporation | 9.42 Million USD | 891.045% |
| iBio, Inc. | -9.75 Million USD | -664.759% |
| Lineage Cell Therapeutics, Inc. | -32.49 Million USD | -129.498% |
| MAIA Biotechnology, Inc. | -7.15 Million USD | -942.752% |
| Matinas BioPharma Holdings, Inc. | -1.28 Million USD | -5720.765% |
| Navidea Biopharmaceuticals, Inc. | 438.44 Thousand USD | 17106.505% |
| NovaBay Pharmaceuticals, Inc. | -390 Thousand USD | -19018.974% |
| NanoViricides, Inc. | -4.79 Million USD | -1454.136% |
| Oragenics, Inc. | -3.17 Million USD | -2251.585% |
| BiomX Inc. | -772 Thousand USD | -9558.549% |
| BiomX Inc. | -772 Thousand USD | -9558.549% |
| Protalix BioTherapeutics, Inc. | 2.64 Million USD | 2916.925% |
| Palatin Technologies, Inc. | -8.93 Million USD | -734.324% |
| Scorpius Holdings, Inc. | 13.85 Million USD | 638.092% |